136 related articles for article (PubMed ID: 30203592)
1. Designing cancer immunotherapy trials with random treatment time-lag effect.
Xu Z; Park Y; Zhen B; Zhu B
Stat Med; 2018 Dec; 37(30):4589-4609. PubMed ID: 30203592
[TBL] [Abstract][Full Text] [Related]
2. Designing therapeutic cancer vaccine trials with delayed treatment effect.
Xu Z; Zhen B; Park Y; Zhu B
Stat Med; 2017 Feb; 36(4):592-605. PubMed ID: 27807870
[TBL] [Abstract][Full Text] [Related]
3. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
Ye T; Yu M
Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
[TBL] [Abstract][Full Text] [Related]
4. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
5. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
6. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
Phadnis MA; Wetmore JB; Mayo MS
Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
[TBL] [Abstract][Full Text] [Related]
7. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
Ding X; Wu J
Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
[TBL] [Abstract][Full Text] [Related]
8. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chu C; Liu S; Rong A
Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
Wu J; Wei J
Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
Wei J; Wu J
Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
[TBL] [Abstract][Full Text] [Related]
11. Treating non-responders: pitfalls and implications for cancer immunotherapy trial design.
Xu Z; Park Y; Liu K; Zhu B
J Hematol Oncol; 2020 Mar; 13(1):20. PubMed ID: 32171307
[TBL] [Abstract][Full Text] [Related]
12. Cancer immunotherapy trial design with delayed treatment effect.
Wu J; Wei J
Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
[TBL] [Abstract][Full Text] [Related]
13. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
[TBL] [Abstract][Full Text] [Related]
14. Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.
Rahman R; Fell G; Ventz S; Arfé A; Vanderbeek AM; Trippa L; Alexander BM
Clin Cancer Res; 2019 Nov; 25(21):6339-6345. PubMed ID: 31345838
[TBL] [Abstract][Full Text] [Related]
15. A flexible and coherent test/estimation procedure based on restricted mean survival times for censored time-to-event data in randomized clinical trials.
Horiguchi M; Cronin AM; Takeuchi M; Uno H
Stat Med; 2018 Jul; 37(15):2307-2320. PubMed ID: 29682762
[TBL] [Abstract][Full Text] [Related]
16. Sample size calculation for the combination test under nonproportional hazards.
Cheng H; He J
Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
[TBL] [Abstract][Full Text] [Related]
17. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Chen TT
BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
[TBL] [Abstract][Full Text] [Related]
18. Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials.
Kaneko Y; Morita S
J Biopharm Stat; 2023 Aug; ():1-20. PubMed ID: 37585719
[TBL] [Abstract][Full Text] [Related]
19. Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect.
Wu J; Zhu L; Li Y
J Biopharm Stat; 2023 Dec; ():1-14. PubMed ID: 38146192
[TBL] [Abstract][Full Text] [Related]
20. Sample size calculation in multi-centre clinical trials.
Harden M; Friede T
BMC Med Res Methodol; 2018 Nov; 18(1):156. PubMed ID: 30497390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
